Michael A. Morse

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2.1K citations · Full text

Life Sciences, Immunology, Oncology +16

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Thierry André, Sara Lonardi, Ka Yeung Mark Wong et al. · Annals of Oncology · 2022 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Liver metastases from breast cancer: Long-term survival after curative resection☆

Markus Selzner, Michael A. Morse, James J. Vredenburgh et al. · Surgery · 2000 · 220 citations

Medicine, Oncology, Surgery +16

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer

Michael A. Morse, Michael J. Overman, Leighanne Hartman et al. · The Oncologist · 2019 · 117 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

Michael A. Morse · PubMed · 2005 · 48 citations

Pharmacy, Pharmacology, Pharmacotherapy +17